Live
- G20 Leaders Will Talk About Climate, Taxes, and Trump's Return in Brazil
- COP29: CDRI announces $8 million funding for 12 projects to address climate crisis
- Anti-Telgu remarks: Actor Kasthuri Shankar moves court for bail
- Samsung AR Smart Glasses Set to Launch in 2025, Featuring Ray-Ban Meta-Like Design
- Kerala Industries Minister confident that new policy will boost plantation sector
- Madras HC plans inter-departmental monitoring committee to combat drug use in TN
- Bihar: Spotted deer dies due to heart attack in Banka district
- Mushtaq Ali T20: Shami to spearhead Bengal bowling attack, Gharami named captain
- Kharge's clarion call to oust Maharashtra's BJP-backed MahaYuti
- Why Ukraine’s Use of US Missiles Against Russia Could Lead to World War 3
Sun Pharma's eye inflammation drug gets USFDA nod
Sun Pharmaceutical Industries, the world\'s fifth largest specialty generic pharmaceutical company and India\'s largest drug maker, received an approval from the US health regulator USFDA for its non-steroid drug BromSite, which is used to treat inflammation and prevent pain in patients undergoing cataract surgery.
New Delhi : Sun Pharmaceutical Industries, the world's fifth largest specialty generic pharmaceutical company and India's largest drug maker, received an approval from the US health regulator USFDA for its non-steroid drug BromSite, which is used to treat inflammation and prevent pain in patients undergoing cataract surgery.
In a BSE filling today, Sun Pharmaceutical Industries stated that its wholly-owned subsidiaries have received approval from the USFDA for its New Drug Application (NDA) related to BromSite for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
The drug has been developed by InSite Vision, which the company had acquired in November 2015, it added.
The company is likely to commercialize BromSite through its newly-formed US-based division Sun Ophthalmics in the second half of 2016, it said.
As per the USFDA, NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the US.
